12th - 13th October 2021 | Germany

Day 3 - Future Technology

8:30 am - 9:00 am Morning Coffee

9:00 am - 9:10 am Chairman's Recap of Day Two

9:10 am - 10:30 am Mini-Workshop

Future Challenges and Opportunities

The bio-manufacturing industry is facing a number of new challenges; with the emergence of new product areas including ATMP’s, increased demands for compliance and reduction in costs. This in turn is creates opportunities for innovation from suppliers and manufacturing groups to provide solutions to these challenges. The aim of this workshop will be to look at the following key areas: 

•Single use monitoring tools / in-process analytical systems
•Aseptically closed manufacturing systems
•Continuous processing
•Sustainability – recycling of single use systems

Tony Hitchcock, Technical Director at Cobra Biologics

Tony Hitchcock

Technical Director
Cobra Biologics

10:30 am - 11:00 am Networking Coffee Break

11:00 am - 11:30 am High Cell Concentration Banking for Seed Train Reduction on Fluoropolymer Single Use Bag

  • Discuss challenges of the industry, including cell culture processes requiring a new seed at each batch
  • Identify a change in strategy for cell banking
  • Understand how to increase cell number in WCB to decrease process time with case study insight
Jonathan Cartoux, Field Application Engineer EMEA Life Sciences at Entegris

Jonathan Cartoux

Field Application Engineer EMEA Life Sciences

11:30 am - 12:10 pm Case Study: Biomanufacturing for Tomorrow (BM4T)

·         Gain insight of a combined USP/DSP line (SUB + 1. column) using disposables and automated systems, and a connected process
·         Uncover the link from early research to phase I to market manufacturing
·         Understand why it is essential to address BM4T in early research and development
Marc Pompiati, Principal Scientist at Roche

Marc Pompiati

Principal Scientist

12:10 pm - 12:50 pm Keeping Up with the Future Demand for ATMPs: The Challenges and Opportunities of Using Disposables in Cell Therapy Manufacturing

·         Discuss the uniqueness of cell therapy and the challenges in using full disposable process
·         Understand the preparations for manufacturing up scaling and readiness for marketing demands
·         What is the best point to move to full SU manufacturing process?
Nadav Eshkol, Development Manager at Pluristem Therapeutics

Nadav Eshkol

Development Manager
Pluristem Therapeutics

12:50 pm - 1:50 pm Networking Lunch

1:50 pm - 2:30 pm The Impact of the 2020 MDR on Biological Evaluation of Medical Devices, Including the Role of Extractables and Leachables in Biological Risk Assessment

• Identify what is meant by biological safety and overview the relevant guidance documents
• Discuss the parts of the MDR which relate to biological safety 
• Will the MDR requirements have an effect on biological safety evaluation going forward? 
Sophie Clewlow, Higher Medical Device Specialist at MHRA

Sophie Clewlow

Higher Medical Device Specialist

2:30 pm - 3:10 pm Single Use Tools for the Personalise Medicine Production

• Look at the expansion in demand for plasmid DNA for gene therapy application
• Discuss how this has led to the rapid production of small high quality batches of multiple plasmid DNA constructs 
• Understand how this increases personalised medicine
• Identify how single use manufacturing tools can provide manufacturing solutions to these novel challenges

Darrell Sleep, Director of Innovation at Cobra Biologics

Darrell Sleep

Director of Innovation
Cobra Biologics

3:10 pm - 3:20 pm Chairman's Summary of Day Three

3:20 pm - 3:50 pm Networking Coffee Break